Medical Pharmacology: Anti-Lipid Drug
Practice Questions
Click on the correct answer.
Which one(s) of the following statements is/are correct?
A primary mechanism of action of statins in management of cardiovascular disease is promoting regression of cardiac vessel narrowing.
Effective use of drugs that lower LDL essentially eliminates residual risk, especially in patients treated with the high-efficacy statins.
Both
Neither
The pro-protein convertase subtilisin kexin-like 9 (PCSK9) it appears to regulate LDL levels in a way that appears relevant to cardiovascular disease development.
True
False
Binding of LDL receptors and PCSK9 (pro-protein convertase subtilisin kexin-like 9 ) increases receptor degradation which promotes higher serum LDL levels.
True
False
LDL-cholesterol baseline levels correlates with long-term cardiovascular risk.
True
False
(A) risk factor(s) associated with coronary heart disease:
Smoking
Hypertension
Type II diabetes
Elevated HDL-C
A & B
A & C
A, B & C
A, B, C & D
Which one(s) of the following statements is/are true?
Higher cholesterol levels are associated with higher coronary heart disease risk
Patients with very high cholesterol levels (>300 mg/sL) account for about 40% of cardiovascular heart disease events.
Both
Neither
Which one(s) of the following disorders represent secondary causes of dyslipidemia with the major effect on cholesterol vs triglyceride levels?
Alcohol use
Hypothyroidism
Diabetes mellitus
All of the above
In terms of coronary heart disease age >45 years in men and >55 years in women represent a risk factor.
True
False
Choose the correct statement(s) concerning coronary heart disease in the type II diabetic patient.
Patients with diabetes exhibit coronary heart disease morbidity 2-4 times higher compared to non-diabetics.
Glucose control provide substantial benefit with respect to coronary heart disease prevention in type II diabetics.
Both
Neither
Administration of statins results in reduced total and vascular disease mortality in the diabetic patient due to prevention of cardiovascular disease events.
